Entera Bio (ENTX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ENTX · Stock Price

USD 1.37-0.78 (-36.28%)

Market Cap: $69.7M

Historical price data

Market Cap: $69.7MPipeline: 6 drugsFounded: 2010HQ: Jerusalem, Israel

Sector Ranking#97 in Drug Delivery & Formulation

Overview

Entera Bio is a clinical-stage biotech focused on transforming injectable peptide therapies into convenient oral tablets using its proprietary N-Tab® drug delivery platform. The company's strategy de-risks development by targeting well-characterized peptides like PTH, with its lead asset, EB613 for osteoporosis, having completed a positive Phase 2 study and a streamlined Phase 3 protocol submitted in early 2026. Backed by a seasoned management team and strategic partnerships, Entera aims to redefine standards of care by improving patient adherence and enabling earlier therapeutic intervention.

Metabolic Bone DiseasesEndocrinologyObesity & Metabolic DiseasesGastrointestinal

Technology Platform

The N-Tab® platform is a proprietary oral drug delivery technology that co-formulates therapeutic peptides with GRAS excipients to stabilize the molecule in the GI tract and transiently enhance intestinal permeability for systemic absorption.

Pipeline

6

6 drugs in pipeline

Drug	Indication	Stage
EnteraBio's Oral Parathyroid Hormone (1-34)	Hypoparathyroidism	Phase 2
EBP05 + Placebo of EBP05	Osteoporosis	Phase 2
EB612 (EBP05) + NATPARA/NATPAR	Hypoparathyroidism	Phase 2
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4...	Hypoparathyroidism	Phase 1
Teriparatide + Oral PTH (1-34)	Drug Safety and Bioavailability	Phase 1

Funding History

3

Total raised:$37M

PIPE$10MUndisclosedNov 15, 2021

IPO$15MUndisclosedJun 15, 2018

Series A$12MPontifaxMar 15, 2016

Opportunities

Entera's lead oral anabolic for osteoporosis (EB613) addresses a multi-billion dollar market with no oral competitors, offering a paradigm shift in treatment convenience.

Success would validate its platform, creating significant value for its pipeline in obesity and rare diseases, potentially attracting partnership or acquisition interest.

Risk Factors

The company faces high clinical risk as EB613 enters pivotal Phase 3 trials, alongside significant financing needs to complete development.

It also competes in crowded markets (e.g., obesity) against large pharma companies with substantial resources.

Competitive Landscape

Entera's primary competition varies by program: injectable anabolics in osteoporosis, conventional therapy in hypoparathyroidism, and injectable GLP-1 agonists in obesity. Its key differentiator is the oral tablet format, protected by a strong IP portfolio around its N-Tab® platform.